Soligenix, Inc. Email Format
Biotechnology ResearchNew Jersey, United States11-50 Employees
In Public Health Solutions, Soligenix advances vaccine and therapeutic candidates, including RiVax for ricin toxin, and programs targeting filoviruses and coronaviruses, employing a heat-stabilization platform to improve stability. The unit has benefited from government funding support from agencies like NIAID, BARDA, and DTRA, reflecting a lifecycle that includes collaboration with public sector partners. Headquartered in Princeton, New Jersey, the firm operates in the biotechnology research sector with a focus on rare diseases and infectious disease initiatives.